ArticleFrontiers in oncology2025
Association of serum vascular endothelial growth factor-C, vascular endothelial growth factor receptor-3, and insulin-like growth factor 1 levels with metastasis and prognosis in patients with nasopharyngeal carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association of serum levels of Vascular Endothelial Growth Factor-C (VEGFC), Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3), and Insulin-like Growth Factor 1 (IGF1) with metastasis and prognosis in patients with nasopharyngeal carcinoma (NPC). Methods: This retrospective study included 298 patients diagnosed with NPC at our institution between January 2022 and December 2023. Patients were categorized based on the presence of metastasis at diagnosis or during follow-up into a metastatic group (n=78) and a non-metastatic group (n=220). Clinical data, including plasma Epstein-Barr virus (EBV) DNA load, were collected, and serum VEGFC, VEGFR-3, and IGF1 levels were measured. Patients were followed up for a mean of (12.02 ± 1.21) months (minimum 12 months). Univariate and multivariate logistic regression analyses were performed to identify factors influencing NPC metastasis. Receiver Operating Characteristic (ROC) curve analysis was used to evaluate the predictive value of these biomarkers for NPC metastasis. Kaplan-Meier survival analysis and log-rank tests were used to evaluate the prognostic value of the biomarkers for OS. Results: Serum levels of VEGFC, VEGFR-3, and IGF1 were significantly higher in the metastatic group compared to the non-metastatic group (P<0.05). Similarly, these markers were significantly elevated in patients with poor prognosis compared to those with good prognosis (P<0.05). Multivariate logistic regression analysis identified advanced T stage, N stage, high plasma EBV DNA load, and elevated serum VEGFC, VEGFR-3, and IGF1 levels as independent risk factors for NPC metastasis. Combined detection of serum VEGFC, VEGFR-3, and IGF1 yielded a significantly higher Area Under the Curve (AUC) for predicting NPC metastasis than individual markers, and a nomogram incorporating all independent risk factors showed excellent predictive performance (C-index: 0.941). Kaplan-Meier analysis revealed that patients with high levels of VEGFC, VEGFR-3, IGF1, or a high-risk score from the combined biomarker model had significantly poorer OS (all P<0.001). Conclusion: Serum levels of VEGFC, VEGFR-3, and IGF1 are significantly correlated with metastasis and poor prognosis in NPC patients. These biomarkers, particularly when combined and integrated with EBV DNA load, serve as valuable indicators for predicting metastatic risk and assessing survival outcomes in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.